COMPOUND, ENDOTHELIN RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION Russian patent published in 2024 - IPC C07D405/14 C07D413/14 A61K31/4439 A61P1/16 A61P11/00 A61P13/12 A61P25/02 A61P35/00 A61P43/00 A61P9/12 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to a compound of formula (1), an endothelin A receptor antagonist, as well as a pharmaceutical composition based thereon. where R¹ and R² are all independently hydrogen or alkyl, R³ and R⁴ are all independently hydrogen or alkyl, or R³ and R⁴ together form an oxo group, R⁵-R⁷ are all independently hydrogen, alkyl, haloalkyl, halogen, alkoxy group or haloalkoxy group, each R⁸ independently denotes alkyl, haloalkyl or halogen, n is integer from 0 to 3, and Ar is described by the following formula (Ar1) or (Ar2): where X and Y denote nitrogen and oxygen, respectively, or oxygen and nitrogen, respectively, R⁹ and R¹⁰ independently denote hydrogen, alkyl, halogenalkyl or halogen, each R¹¹ independently denotes an alkyl, haloalkyl, halogen, alkoxy group or haloalkoxy group and m is integer from 0 to 3, where: alkyl represented by each of R¹, R², R³, R⁴, R⁵-R⁷, R⁸, R⁹, R¹⁰ and R¹¹, is an alkyl having from 1 to 6 carbon atoms, where the haloalkyl represented by each of R⁵-R⁷, R⁸, R⁹, R¹⁰ and R¹¹ is a haloalkyl having from 1 to 6 carbon atoms, where alkoxy represented by each of R⁵-R⁷ and R¹¹ is alkoxy having from 1 to 6 carbon atoms, where the haloalkoxy represented by each of R⁵-R⁷ and R¹¹ is a haloalkoxy having from 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

EFFECT: novel compounds which can be used for preventing or treating a disease associated with the endothelin A receptor are obtained.

15 cl, 7 tbl, 13 ex